Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion on March 11, 2024. As of May 16, 2024, the agreement was revised and under the revised terms Hyundai Bioscience will now acquire 30.33% stake, CnPharm will acquire 2.89% stake and Yeonjin Kim will acquire 1.69% stake in ADM Korea. Transaction is expected to May 20, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,310 KRW | +0.61% | -3.07% | +70.79% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
20,300 KRW | +3.89% | +1.25% | 58Cr | ||
3,750 KRW | -4.94% | +4.46% | 8.66Cr | ||
3,310 KRW | +0.61% | -3.07% | 5.06Cr | ||
1st Jan change | Capi. | |
---|---|---|
+70.79% | 5.06Cr | |
+43.36% | 5.46TCr | |
-5.31% | 3.99TCr | |
+37.52% | 3.88TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+25.12% | 1.22TCr | |
+0.04% | 1.22TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- A187660 Stock
- News ADM Korea Inc.
- Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.